Editas Medicine Announces Closing of Initial Public Offering and Full Exercise of Option to Purchase Additional Shares

Editas Medicine Announces Closing of Initial Public Offering and Full Exercise of Option to Purchase Additional Shares

February 8, 2016

CAMBRIDGE, Mass., Feb. 08, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT) today announced the closing of its initial public offering of 6,785,000 shares of its common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions, including 885,000 additional shares of common stock issued upon the exercise in full by the underwriters of their over-allotment option.

Seres Therapeutics Announces Academic Collaborations to Support Development of Microbiome Therapeutics for Inflammatory Bowel Disease

Seres Therapeutics Announces Academic Collaborations to Support Development of Microbiome Therapeutics for Inflammatory Bowel Disease

May 4, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 4, 2016-- Seres Therapeutics, Inc. (NASDAQ: MCRB), a leading microbiome therapeutics platform company, today announced it has entered into two separate research collaborations with leading academic groups to support Seres’ ongoing development of the first potential microbiome therapeutics for inflammatory bowel disease (IBD).

Editas Medicine Achieves Milestone under its Collaboration with Juno Therapeutics

Editas Medicine Achieves Milestone under its Collaboration with Juno Therapeutics

May 4, 2016

CAMBRIDGE, Mass., May 04, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, announced today that it has achieved a $2.5 million milestone under its collaboration with Juno Therapeutics, Inc. (NASDAQ:JUNO) for technical progress in a research program to create engineered T cells with chimeric antigen receptors (CAR) and T cell receptors (TCR) to treat cancer. Editas and Juno are pursuing three research programs utilizing Editas’ genome editing technologies, including CRISPR/Cas9, with Juno’s CAR and TCR technologies.

Acceleron Pharma Reports First Quarter 2016 Financial and Operational Results

Acceleron Pharma Reports First Quarter 2016 Financial and Operational Results

May 5, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body's ability to rebuild and repair its own cells and tissues, today provided a corporate update and reported financial results for the first quarter ended March 31, 2016.

Agios Reports First Quarter 2016 Financial Results

Agios Reports First Quarter 2016 Financial Results

May 5, 2016

CAMBRIDGE, Mass., May 05, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today reported business highlights and financial results for the first quarter ended March 31, 2016.

Seres Therapeutics Announces Achievement of Target Enrollment of SER-109 Phase 2 Study for the Prevention of Recurrent Clostridium difficile Infection

Seres Therapeutics Announces Achievement of Target Enrollment of SER-109 Phase 2 Study for the Prevention of Recurrent Clostridium difficile Infection

May 2, 2016

Phase 2 data expected in mid-2016 New SER-109

Expanded Access Program initiated at Phase 2 clinical sites

Visterra Appoints Two Industry Leaders to its Board of Directors

Visterra Appoints Two Industry Leaders to its Board of Directors

April 21, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Visterra, Inc., a clinical-stage biotechnology company, today announced the appointment of Bernadette Connaughton, Head, European Markets, Canada and Australia of Bristol-Myers Squibb, and Steven Holtzman, former Executive Vice President, Corporate Development of Biogen, to the company’s board of directors. Ms. Connaughton and Mr.

Avedro Receives FDA Approval for Photrexa® Viscous, Photrexa® and the KXL® System for Corneal Cross-Linking

Avedro Receives FDA Approval for Photrexa® Viscous, Photrexa® and the KXL® System for Corneal Cross-Linking

April 18, 2016

Avedro, Inc., an ophthalmic pharmaceutical and medical device company, has received approval from the U.S. Food and Drug Administration (FDA) for Photrexa Viscous, Photrexa and the KXL System. Photrexa Viscous and Photrexa are photoenhancers indicated for use with the KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus. Avedro’s Photrexa Viscous, Photrexa and the KXL System represent a first-in-class therapeutic treatment for this sight threatening indication.

Syros Pharmaceuticals Presents New Data Demonstrating Significant Anti - Tumor Activity of its Selective CDK7 Inhibitor in Preclinical Models of Acute Myeloid Leukemia

Syros Pharmaceuticals Presents New Data Demonstrating Significant Anti - Tumor Activity of its Selective CDK7 Inhibitor in Preclinical Models of Acute Myeloid Leukemia

April 20, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals today announced that SY-1365, a first-in-class potent and selective cyclin-dependent kinase 7 (CDK7) inhibitor, was observed to induce durable tumor regression and prolong survival in in vivo models of acute myeloid leukemia (AML). These data were presented at the American Association of Cancer Research (AACR) Annual Meeting in New Orleans. Based on the strong efficacy and safety data, Syros selected SY-1365 as its development candidate and plans to file an Investigational New Drug (IND) application with the U.S.

Syros Pharmaceuticals Presents Data Demonstrating Significant Anti - Cancer Activity of SY - 1425 in Preclinical Models of Acute Myeloid Leukemia

Syros Pharmaceuticals Presents Data Demonstrating Significant Anti - Cancer Activity of SY - 1425 in Preclinical Models of Acute Myeloid Leukemia

April 18, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals today announced that SY-1425, a potent and selective retinoic acid receptor alpha (RARα) agonist, was observed to inhibit the growth of cancer cells and prolong survival in in vivo models of acute myeloid leukemia (AML) with a novel RARA biomarker discovered by the Company. The biomarker was found in approximately 25 percent of AML and myelodysplastic syndrome (MDS) patient tissue samples. These data were presented at the American Association of Cancer Research (AACR) Annual Meeting in New Orleans.